Regeneron backs $75M series A for antibody upstart Infinimmune Read more →
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder Read more →
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms Read more →
